# Physostigmine (Physostigma venenosum alkaloid)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/physostigmine-physostigma-venenosum-alkaloid
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Physostigma venenosum alkaloid, Eserine, Physostigmine hemisulfate, Physostigmine salicylate, Antilirium

## Overview

Physostigmine (eserine, C₁₅H₂₁N₃O₂) reversibly inhibits [acetylcholine](/ingredients/condition/cognitive)sterase (AChE, UniProt P22303), preventing hydrolysis of acetylcholine and thereby amplifying cholinergic neurotransmission at both muscarinic and nicotinic receptors. In controlled volunteer pharmacokinetic studies, oral controlled-release doses of 9–15 mg physostigmine salicylate produced dose-proportional plasma concentrations and corresponding AChE inhibition, though poor oral bioavailability and a narrow therapeutic index restrict its clinical utility to acute anticholinergic toxicity reversal and select ophthalmic indications.

## Health Benefits

- **Reversal of Anticholinergic Toxicity**: Physostigmine penetrates the blood-brain barrier and inhibits AChE centrally and peripherally, rapidly reversing delirium, tachycardia, and hyperthermia caused by atropine, tricyclic antidepressants, or antihistamine overdose; it remains the only cholinesterase inhibitor routinely used for central anticholinergic crisis in emergency medicine.
- **Reduction of Intraocular Pressure (Glaucoma)**: Topical ophthalmic formulations (0.25–0.5% solution or ointment) stimulate ciliary muscle contraction and pupillary miosis via muscarinic receptor activation, improving aqueous humor outflow and lowering intraocular pressure in open-angle glaucoma, though it has been largely superseded by safer agents.
- **Neuromuscular Junction Support in Myasthenia Gravis**: By inhibiting AChE at the neuromuscular junction, physostigmine prolongs acetylcholine residence time at nicotinic receptors (CHRNA1/CHRND subunits), partially compensating for autoantibody-mediated receptor loss, though neostigmine and pyridostigmine are preferred due to their superior peripheral selectivity.
- **[Cognitive Enhancement](/ingredients/condition/cognitive) in Alzheimer's Disease (Investigational)**: Early clinical trials examined physostigmine salicylate for memory and cognition in Alzheimer's disease, with the rationale that restoring cholinergic tone in the nucleus basalis of Meynert improves cortical acetylcholine levels; however, poor oral bioavailability, short half-life (~30 minutes), and gastrointestinal toxicity limited clinical success compared to later agents like donepezil.
- **Attenuation of Postoperative Delirium**: Intravenous physostigmine (1–2 mg IV) has been used perioperatively to reverse central anticholinergic syndrome following anesthesia involving scopolamine or other anticholinergic agents, with case series and small trials documenting rapid resolution of confusion and agitation within minutes of administration.
- **Research Tool for Cholinergic Pathway Characterization**: Physostigmine serves as a gold-standard pharmacological probe in neuroscience research to acutely and reversibly elevate synaptic acetylcholine, enabling mechanistic dissection of muscarinic and nicotinic receptor contributions to memory encoding, [sleep architecture](/ingredients/condition/sleep) (particularly REM enhancement), and autonomic regulation in both animal models and human experimental paradigms.

## Mechanism of Action

Physostigmine acts as a reversible, competitive inhibitor of [acetylcholine](/ingredients/condition/cognitive)sterase (AChE, EC 3.1.1.7; UniProt P22303) by binding to the active-site serine residue (Ser203) via its carbamate moiety, forming a carbamylated enzyme intermediate that hydrolyzes approximately 1,000-fold more slowly than the acetylated intermediate produced by acetylcholine itself, yielding an effective inhibition duration of 30–60 minutes. Inhibition of AChE prevents hydrolysis of acetylcholine in cholinergic synapses, elevating synaptic ACh concentrations and prolonging its interaction with both muscarinic receptors (M1–M5, coupled to Gq/Gi signaling cascades) and nicotinic acetylcholine receptors (nAChRs, including CHRNA4/CHRNB2 heteromers in the CNS and CHRNA1-containing pentamers at the neuromuscular junction). Unlike quaternary ammonium cholinesterase inhibitors such as neostigmine, physostigmine's tertiary amine structure at physiological pH allows it to cross the blood-brain barrier via lipid diffusion, enabling simultaneous central (hippocampal, cortical) and peripheral (autonomic ganglia, neuromuscular junction) cholinergic amplification. Secondary effects include stimulation of presynaptic M2 autoreceptors that modulate further ACh release, indirect nAChR-mediated [dopamine](/ingredients/condition/mood) and norepinephrine release in limbic regions, and activation of parasympathetic end-organs producing the full spectrum of cholinomimetic responses including bradycardia, increased glandular secretions, miosis, and enhanced gastrointestinal motility.

## Clinical Summary

In Alzheimer's disease clinical trials conducted primarily between 1985 and 1998, oral and intravenous physostigmine produced statistically significant but clinically modest improvements in selective memory tests in a subset of patients, with effect sizes generally small and highly variable across individuals; no pivotal Phase III RCT successfully demonstrated sufficient efficacy and tolerability to support regulatory approval. Pharmacokinetic trials (n=5–6) with controlled-release oral formulations confirmed dose-proportional AChE inhibition at 9–15 mg doses, providing mechanistic proof-of-concept but limited generalizability. For anticholinergic toxicity reversal, retrospective case series and prospective emergency medicine studies report rapid (minutes) resolution of central and peripheral anticholinergic signs following IV physostigmine 1–2 mg, with a favorable response rate, though randomized controlled comparisons against supportive care alone are ethically constrained and methodologically limited. Overall, confidence in physostigmine's clinical benefits is moderate for toxidrome reversal and ophthalmic use based on historical evidence, but low-to-moderate for [cognitive](/ingredients/condition/cognitive) indications due to inadequate trial size, short duration, and unresolved bioavailability challenges.

## Nutritional Profile

Physostigmine is not a nutritional compound and has no meaningful macronutrient, micronutrient, or caloric profile relevant to dietary science. It is a tricyclic indoline alkaloid (C₁₅H₂₁N₃O₂, MW 275.35 g/mol) containing a methylcarbamate group and two stereocenters at the ring junction carbons (C3a and C8a, both in the (3aS,8aR) configuration in the naturally occurring form), which confer both AChE inhibitory activity and high inherent toxicity. No vitamins, minerals, dietary fiber, or beneficial phytochemical classes beyond its pharmaceutical alkaloid activity are associated with this compound. Bioavailability via oral route is poor for physostigmine salicylate due to first-pass hepatic [metabolism](/ingredients/condition/weight-management), rapid plasma esterase hydrolysis (plasma half-life approximately 15–40 minutes), and pH-dependent absorption; parenteral administration bypasses these limitations but is exclusively a medical intervention.

## Dosage & Preparation

- **Intravenous/Intramuscular (Acute Anticholinergic Toxicity)**: 0.5–2 mg IV administered slowly over 5 minutes in adults; may repeat every 10–30 minutes as needed; pediatric dose 0.02 mg/kg IV; administered only in monitored clinical settings with atropine available as antidote.
- **Ophthalmic Solution (Glaucoma)**: 0.25% or 0.5% physostigmine sulfate eye drops instilled 1–4 times daily in the affected eye; largely superseded by [prostaglandin](/ingredients/condition/inflammation) analogues and beta-blockers in contemporary practice.
- **Ophthalmic Ointment**: 0.25% physostigmine ointment applied to the conjunctival sac once or twice daily for sustained miotic effect in glaucoma management.
- **Controlled-Release Oral Tablets (Investigational/Research)**: 9–15 mg physostigmine salicylate in controlled-release formulations studied in volunteer pharmacokinetic trials; no approved oral formulation is currently marketed.
- **Pharmaceutical Purity Standards**: Physostigmine hemisulfate (≥98% HPLC purity) solubilizes to approximately 32.44 mg/mL in water at 100 mM, used in research and compounding; physostigmine free base is poorly water-soluble and requires acidic salt formation for injectable preparations.
- **Standardization**: There are no supplemental standardization percentages; pharmaceutical grades specify ≥98% purity by HPLC; no nutritional supplement forms exist or are recommended.
- **Timing Note**: Oral bioavailability is poor and erratic for salicylate forms; parenteral routes are preferred for reliable pharmacokinetic profiles; duration of AChE inhibition is approximately 30–60 minutes regardless of route.

## Safety & Drug Interactions

Physostigmine carries a narrow therapeutic index and is considered highly toxic; the LD₅₀ in mice is approximately 3 mg/kg, and clinical toxicity manifests as a cholinergic crisis characterized by bradycardia, excessive salivation and lacrimation, bronchospasm, miosis, urinary and fecal incontinence, muscle fasciculations, and seizures — symptoms that are the direct pharmacological consequence of excessive AChE inhibition and must be treated promptly with atropine (1–4 mg IV) as a competitive muscarinic antagonist antidote. Drug interactions are clinically significant: concurrent use with other cholinesterase inhibitors (donepezil, rivastigmine, neostigmine), depolarizing neuromuscular blockers (succinylcholine), or cholinergic agonists (bethanechol, pilocarpine) risks additive cholinergic toxicity; conversely, anticholinergic drugs (atropine, scopolamine, tricyclic antidepressants) antagonize its effects. Absolute contraindications include active asthma or severe reactive airway disease (bronchospasm risk), mechanical obstruction of the gastrointestinal or urinary tract, peripheral vascular disease, bradycardia or atrioventricular block, and known hypersensitivity; relative contraindications include Parkinson's disease (worsening tremor) and epilepsy. Physostigmine is classified as a pregnancy Category C agent with insufficient safety data for use during pregnancy or lactation; it is not approved for self-administration, over-the-counter sale, or supplemental use under any regulatory framework, and no maximum safe dose exists outside of closely monitored clinical environments.

## Scientific Research

The clinical evidence base for physostigmine is characterized by small, often uncontrolled or early-phase studies reflecting its status as a decades-old compound that predates modern RCT methodology; the volume of large, placebo-controlled trials is limited compared to contemporary cholinesterase inhibitors such as donepezil. A 1991 pharmacokinetic study in 5–6 healthy volunteers demonstrated dose-proportional plasma concentrations and AChE inhibition following controlled-release physostigmine salicylate at 9 mg, 12 mg, and 15 mg oral doses, establishing a quantitative relationship between exposure and enzyme inhibition. Alzheimer's disease trials from the late 1980s and 1990s showed modest, inconsistent improvements in [memory](/ingredients/condition/cognitive) tasks with physostigmine salicylate, but these studies were typically short-duration, enrolled fewer than 100 participants, and failed to overcome the compound's pharmacokinetic limitations; the drug never received FDA approval for Alzheimer's. Emergency medicine case series and small prospective studies support its efficacy for anticholinergic toxidrome reversal, and ophthalmic efficacy is established through historical comparative trials, but the overall evidence base would score conservatively due to age, small sample sizes, and the absence of modern systematic reviews or meta-analyses specific to physostigmine.

## Historical & Cultural Context

Physostigmine was first isolated from the Calabar bean in 1864 by Scottish chemists Thomas Fraser and John Jobst, representing one of the earliest alkaloids extracted from a West African plant source. In Efik tribal culture of the Niger Delta region, Calabar beans ('esere nuts') were administered as a trial by ordeal: an accused individual ingested the beans, and survival was interpreted as proof of innocence — a practice that paradoxically exploited the bean's cholinergic toxicity, as rapid ingestion of large quantities induced vomiting and evacuation before lethal absorption, while slower, more deliberate ingestion by the 'guilty' (who may have harbored more anxiety and slower peristalsis) proved fatal. The compound was introduced into ophthalmology in 1877 by Ludwig Laqueur for glaucoma treatment, becoming one of the first pharmacological agents used to lower intraocular pressure, and its use in myasthenia gravis was pioneered in the 1930s by Mary Walker. The total synthesis of physostigmine has become a benchmark challenge in synthetic organic chemistry, with over 71 published synthetic routes (33 racemic, 38 enantiopure) attesting to its structural complexity and enduring scientific interest.

## Synergistic Combinations

In emergency and critical care contexts, physostigmine is occasionally paired with benzodiazepines (e.g., lorazepam) when anticholinergic toxicity is complicated by seizures, as benzodiazepines address GABAergic seizure activity while physostigmine reverses the underlying cholinergic deficit; however, this combination requires careful titration to avoid respiratory depression. Historical Alzheimer's research explored combining physostigmine with lecithin (phosphatidylcholine) as a precursor-loading strategy to increase central [acetylcholine](/ingredients/condition/cognitive) synthesis while simultaneously reducing its degradation, though controlled trials showed inconsistent additive benefit. In pharmacological research models, physostigmine is co-administered with muscarinic receptor subtype-selective antagonists (e.g., scopolamine for M1/M2 blockade, pirenzepine for M1 selectivity) to dissect the receptor-specific contributions of elevated synaptic acetylcholine, making it a mechanistic probe rather than a synergistic supplement combination.

## Frequently Asked Questions

### What is physostigmine used for medically?

Physostigmine is used medically to reverse anticholinergic toxicity — overdose from drugs like atropine, scopolamine, or tricyclic antidepressants — by inhibiting acetylcholinesterase and restoring cholinergic neurotransmission. It is also used as a topical ophthalmic agent (0.25–0.5% solution) for open-angle glaucoma and has been investigated for myasthenia gravis and Alzheimer's disease, though newer agents are preferred for both of the latter indications.

### What are the side effects and dangers of physostigmine?

Physostigmine's side effects reflect excessive cholinergic stimulation: bradycardia, bronchospasm, increased secretions, nausea, vomiting, diarrhea, urinary incontinence, muscle fasciculations, and potentially life-threatening seizures or respiratory failure at toxic doses. With an LD₅₀ of approximately 3 mg/kg in mice and a narrow therapeutic index, it must be administered only in monitored clinical settings with atropine immediately available as an antidote.

### How does physostigmine work to reverse anticholinergic poisoning?

Physostigmine inhibits acetylcholinesterase (AChE) by carbamylating the enzyme's active-site serine residue (Ser203), preventing breakdown of acetylcholine for approximately 30–60 minutes. Because it is a tertiary amine, it crosses the blood-brain barrier to restore both central and peripheral acetylcholine levels, directly counteracting the delirium, tachycardia, mydriasis, and hyperthermia caused by muscarinic receptor blockade from anticholinergic agents.

### Is physostigmine available as a supplement or over the counter?

Physostigmine is not available as a dietary supplement or over-the-counter product and has no approved supplemental use; it is a prescription-only pharmaceutical due to its high toxicity, narrow therapeutic index, and the requirement for medical supervision during administration. The Calabar bean from which it is derived is itself considered a toxic plant, and no safe nutritional formulation of physostigmine exists.

### What is the difference between physostigmine and other cholinesterase inhibitors like donepezil?

Physostigmine is a naturally derived, reversible carbamate cholinesterase inhibitor with a very short plasma half-life (approximately 15–40 minutes), poor oral bioavailability, and broad central and peripheral activity that makes it useful for acute toxicity reversal but poorly suited for chronic conditions. Donepezil, by contrast, is a synthetic piperidine-based AChE inhibitor with a half-life of approximately 70 hours, predictable oral absorption, and a more favorable safety profile that makes it suitable for daily oral dosing in Alzheimer's disease — a gap in tolerability and pharmacokinetics that physostigmine could never bridge despite earlier investigation.

### What is the difference between physostigmine's central and peripheral effects in treating anticholinergic poisoning?

Physostigmine is unique among cholinesterase inhibitors because it crosses the blood-brain barrier and works both centrally (reversing delirium and confusion in the brain) and peripherally (reducing tachycardia and hyperthermia in the body). This dual action makes it superior to quaternary ammonium agents like neostigmine, which only work peripherally because they cannot cross the blood-brain barrier. The central reversal of anticholinergic effects is critical in emergency settings, as it addresses the life-threatening neurological symptoms that dominate severe poisoning cases.

### Why is physostigmine considered a last-resort medication rather than a first-line treatment?

Physostigmine carries significant risks of cholinergic crisis (excessive acetylcholine buildup) if dosed incorrectly or given to patients with certain underlying conditions, including cardiac arrhythmias or asthma. Medical protocols prioritize supportive care, benzodiazepines for seizures, and cooling measures before physostigmine is administered, reserving it specifically for severe central anticholinergic toxicity unresponsive to other interventions. The narrow therapeutic window and potential for rapid complications require that physostigmine be given only in controlled medical settings with continuous monitoring and resuscitation equipment available.

### How does physostigmine's mechanism differ from newer Alzheimer's drugs like donepezil in practical emergency use?

While both physostigmine and donepezil inhibit acetylcholinesterase, physostigmine acts rapidly (within minutes) with a short half-life, making it ideal for acute anticholinergic poisoning requiring immediate reversal. Donepezil and similar agents are designed for chronic neurodegenerative disease with slow onset and prolonged action, unsuitable for emergency toxicology. Physostigmine's quick onset and offset allow clinicians to rapidly titrate treatment and reverse effects if cholinergic toxicity develops, whereas longer-acting agents cannot be quickly reversed.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*